Skip to main content
Clinical Trials/NCT04169503
NCT04169503UnknownNot Applicable

Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events in Patients With Cancer: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database

University Hospital, Caen1 site in 1 country17,562 target enrollmentStarted: October 14, 2019Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Enrollment
17,562
Locations
1
Primary Endpoint
Rate of occurrence of second immune-related adverse events (irAEs)

Study Overview

Brief Summary

Although immune checkpoint inhibitors (ICIs) have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE.

Our objective was to investigate the safety of ICI rechallenge after an irAE using the WHO pharmacovigilance database

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction,
  • consecutive individual case safety reports present in VigiBase reporting an irAEs associated to at least one immune checkpoint inhibitor.

Exclusion Criteria

  • Chronology not compatible between the drug and the toxicity.

Outcomes

Primary Outcomes

Rate of occurrence of second immune-related adverse events (irAEs)

Time Frame: Number of case reported in the World Health Organization (WHO) of individual safety case reports, through study completion (an average of 2 months).

percentage of cases experiencing a second irAE among the rechallenged cases

Secondary Outcomes

  • Description of cases experiencing an initial irAEs(Number of case reported in the World Health Organization (WHO) of individual safety case reports, through study completion (an average of 2 months)..)
  • Description of the rechallenge cases(Number of case reported in the World Health Organization (WHO) of individual safety case reports, through study completion (an average of 2 months)..)
  • Description of the clinical features of cases experiencing a second irAEs(Number of case reported in the World Health Organization (WHO) of individual safety case reports, through study completion (an average of 2 months)..)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials